Souza MM, Cruz DL

Idioma: Español
Referencias bibliográficas: 25
Paginas: 67-70
Archivo PDF: 387.02 Kb.

RESUMEN

Se describen las características clínicas generales del trastorno por consumo de sustancias y su relación comórbida con el trastorno depresivo, a efecto de revisar su importancia epidemiológica, desde la óptica de una práctica clínica preocupada por su amplia repercusión social. Ambas formas de manifestación del trastorno depresivo –el que antecede y el que deriva de la patología adictiva–, a menudo no son diagnosticadas por el personal de salud. Tal subestimación agrava el manejo de la comorbilidad, en especial el relativo a la población femenina, respecto de la cual existen aún pocos trabajos publicados. Además, se presentan las principales características de los modelos contemporáneos de personalidad ligados al consumo de psicotrópicos, como elementos a reconocer para su registro diagnóstico-terapéutico. Se destaca el reconocimiento clínico de los pacientes y el adecuado suministro de educación para la salud con miras a lograr la obtención de mejores pronósticos rehabilitatorios a largo plazo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Souza y Machorro M. Diagnóstico y tratamiento de los Síndromes Adictivos. México: Editorial Ciencia y Cultura Latinoamérica; 2000.

2. Swendsen JD, Merikangas KR. The comorbidity of depression and substance use disorders. Clin Psychol Rev 2000; 20: 173-89.

3. National Institute of Mental Health. Mental disorders in America. Available at: www.nimh.nih. gov/publicat/ numbers/cfm. Accessed June 25, 2003.

4. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.

5. Sattar SP, Markert MJ, Petty BSC. Addiction Training Scale: Pilot Study of a Self-Report Evaluation tool for psychiatry residents. Academic Psychiatry 2004; 28: 3.

6. Grilo CM, Martino S, Walker ML, Becker DF, Edell WS, McGlashan TH. Psychiatric comorbidity differences in male and female adult psychiatric in patients with substance use disorders. Compr Psychiatry 1997; 38: 155-9.

7. Chander E, McCaul ME. Co-occurring psychiatric disorders in women with addictions. Obstet Gynecol Clin N Am 2003; 1(30): 469-81.

8. Greenberg WM, Ritvo JI, Fazzio L. A survey of addiction training programming in psychiatry residencies. Academic Psychiatry 2002; 26: 105-9.

9. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105.

10. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 54: 313-21.

11. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 2001; 158: 1184-90.

12. Kendler KS, Bulik CM, Silberg J, Hettema JM, Myers J, Prescott CA. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and co-twin control analysis. Arch Gen Psychiatry 2000; 57: 953-9.

13. Substance abuse and mental health services administration. New national study on substance use among women in the United States released. Available at: www.hhs.gov/news/press/ 1997pres/970922.html. Accessed June 25, 2003.

14. Cloninger CR, Bohman M, Sigvardsson S. Inheritance of alcohol abuse: cross-fostering analysis of adopted men. Arch Gen Psychiatry 1981; 38(8): 861-8.

15. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236: 410-6.

16. Parsian A, Cloninger CR. Serotonergic pathway genes and subtypes of alcoholism: association studies. Psychiatr Genet 2001; 11: 89-94.

17. Meszaros K, Lenzinger E, Hornik K, Fureder T, Willinger U. The tridimensional personality questionnaire as a predictor of relapse in detoxified alcohol dependents. The European fluvoxamine in alcoholism study group. Alcohol Clin Exp Res 1999; 23: 483-6.

18. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599-608.

19. Souza y MM. Personalidad y Adicciones. Rev Mex Neuroci 2005; 6(4): 336-45.

20. Malhotra AK, Murphy GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-96.

21. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284: 963-71.

22. Sacks S, Ries RK. Substance abuse treatment for persons with co-occurring disorders Treatment Improvement Protocol (TIP) Series 42. U.S. Department of Health and Human Services. Public Health Service. Substance Abuse & Mental Health Services Administration, SAHMSA; 2005.

23. Nuevas Estrategias en Potenciación Para Mejores Resultados en Depresión. Material de Apoyo Educativo. Glaxo- Smith-Kline Laboratories. American Psychiatric Association (APA); 2006.

24. Brems C, Johnson ME, Bowers L, Lauver B, Mongeau VA. Comorbidity training needs at a state psychiatric hospital. Adm Policy Ment Health 2002; 30: 109-20.

25. Vallejo-Nájera. Ante la depresión. Madrid: Editorial luz, 1987.